OVERVIEW:
The Indian Medical research organisers have identified 17-18 specific biomarkers which can be used in the diagnosis and prognosis of Cancer. This has expected to change approach of clinician in diagnosis and prevention of cancer treatment. ICMR Journal report of Cancer Biomarkers –current perspective reveals that “Clinical oncology is poised to enter a new era in which cancer detection, diagnosis, and treatment will be guided increasingly by the molecular attributes of the individual patient, acquired from several different sources viz., tumour tissue, host cells/tissues that influence tumour behaviour and body fluids”.
http://icmr.nic.in/ijmr/2010/august/0803.pdf

The drug delivery technology landscape is rapidly evolving with new classes of pharmaceuticals and biologics fuelling this revolution. The growth of generic pharmaceutical business in India forces to bring innovative drug delivery system to differentiate their products in the global markets. According to minister of state for HRD Shashi Tharoor, “The Indian institute of science has recently invented a painless drug delivery system “The device uses supersonic shock waves for painless delivery of medicines into the body”.

One of the major Challenges identified by Indian medical practitioners and planning commission is growth of ageing population and increasing incidents of Cancer in rural India. Similarly the India Psychiatry Association identified need to integrate palliative care into health-care training and the national medical, nursing and allied health council should structure and implement palliative care education into basic health-care training

WHO SHOULD PARTICIPATE?

If you say “Yes” to one of the following questions, this webinar is for you;
1. Do you have an interest in doing business in exponential growth Molecular
diagnostic market for Cancer treatment?
2. Do you conduct research in drug delivery system or supply products in this
segment?

3. Are you looking for doing in-licensing, joint venture and co branding innovative
UK cancer products in Oncology treatment and nutrition support?
4. Are you ready to share your knowledge, expertise in palliative care and end of life
care in cancer with Indian Market on commercial basis?

OBJECTIVES:
 To understand requirements of advanced diagnostics and nutrition products (Enthral and parental)for successful oncology practice in India
 Affordable cancer treatment and need for adapting effective drug delivery system in Indian formulations
 Opportunity for International companies in “Holistic approach of Cure and care of Cancer patients in India”
 One to one Q&A opportunity with Mr Maju Jacob, UKTI -Healthcare Sector Lead for India

SPEAKER:
Maju Jacob- UKTI – Healthcare Sector Lead –India

Maju Jacob has 17 years industry experience in Asian Markets (India and Middle East) with leading Oncology Therapy, Healthcare services and Drug delivery Companies, namely Baxter Healthcare USA, Sorin Bio-Medical USA and Apollo Hospital Group India.

He has been engaged in implementing bone marrow collection and cell therapy system in various parts of Asia. In his tenure with Baxter he has handled drug delivery system in chemotherapy and parental nutrition. He has started his career with Organon (Akzo-
Nobel Group) for launching the first closed oral nutrition system and ready to feed sterile nutrition for Oncology and burns centres in India (1995).

In the last 18 months Jacob was successful in helping over fifty British companies to do business in India.
FOR FURTHER INFORMATION ON THE SECTOR OR UPCOMING EVENTS:
Namrata Devalla
Trade and Investment Adviser, UK Trade & Investment- India
Email: Namrata.Devalla@fco.gov.uk

Or

Menino Marques
Asst. Trade & Investment Adviser , UK Trade & Investment –India
E-Mail: Menino.Marques@fco.gov.uk